Celcuity (CELC) Price & Analysis

Compare

397 Followers

CELC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.58 - $63.06

Previous CloseN/A

Volume14.25K

Average Volume (3M)935.56K

Market Cap

$1.92B

Enterprise Value$513.93M

Total Cash (Recent Filing)$205.69M

Total Debt (Recent Filing)$98.71M

Price to Earnings (P/E)―

Beta0.26

Next Earnings

Nov 17, 2025

EPS Estimate

-1.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.04

Shares Outstanding42,426,712

10 Day Avg. Volume1,042,692

30 Day Avg. Volume935,559

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.27

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-16.52K

Enterprise Value/Ebitda-4.38

Forecast

1Y Price Target

$76.33

Price Target Upside51.12% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsCelcuity reported positive topline results from the PIK3CA WT portion of the Phase 3 VIKTORIA-1 trial testing their pan-PI3K/mTOR inhibitor, gedatolisib, for ER+ breast cancer patients.

Financial FlexibilityThe latest amendment increases the total term loan facility size up to $500 million, significantly enhancing the company's financial strength.

Regulatory ProgressThe FDA agreed to accept the NDA for Celcuity's pan-PI3K/mTOR inhibitor, gedatolisib, under the agency's Real-Time Oncology Review program.

Bears Say

Safety ConcernsSafety data were limited in the topline, but CELC indicated that the profile was better than that seen in the Ph1b, with lower discontinuation rates, hyperglycemia, and stomatitis.

Short InterestShort Interest (% Float) is at 23.9%.

Celcuity News

Guggenheim starts Celcuity with Buy on breast cancer potential

Guggenheim last night initiated coverage of Celcuity (CELC) with a Buy rating and $110 price target The firm’s...

12d ago

CELC

Celcuity initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Celcuity (CELC) with a Buy rating and $110 price target Published first on TheFly...

13d ago

CELC

Short Report: Celcuity short interest at two-year high

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

21d ago

AEVA

CELC

Optimistic Buy Rating for Celcuity Amid Anticipated PIK3CA Mutant Cohort Results in VIKTORIA-1 Study

Analyst Gil Blum from Needham reiterated a Buy rating on Celcuity and keeping the price target at $70.00....

1d ago

CELC

Celcuity’s Enhanced Financial Flexibility and Strategic Progress Justify Buy Rating

Leerink Partners analyst Andrew Berens has maintained their bullish stance on CELC stock, giving a Buy rating yesterday....

23d ago

CELC

Celcuity Expands Credit Facility to $500 Million

The latest update is out from Celcuity ( ($CELC) ). On September 9, 2025, Celcuity Inc. announced an...

24d ago

CELC

Celcuity Inc. Earnings Call: Clinical Progress and Financial Fortification

Celcuity Inc. (($CELC)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

CELC

Celcuity’s Gedatolisib Gains Momentum with FDA’s RTOR Program and Promising Phase 3 Trial Results

In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Celcuity, with a...

1M ago

CELC

Celcuity to initiate gedatolisib NDA submission

Celcuity (CELC) announced the FDA agreed to accept its new drug application for gedatolisib in HR+/HER2- advanced breast...

1M ago

CELC

Celcuity price target raised to $66 from $50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Celcuity (CELC) to $66 from $50 and keeps a Buy...

2M ago

CELC

Celcuity’s Geda Triplet Therapy Shows Promising Phase III Results, Justifying Buy Rating

TD Cowen analyst Tara Bancroft has maintained their bullish stance on CELC stock, giving a Buy rating today....

2M ago

CELC

Celcuity’s Strong Prospects: Buy Rating Affirmed Amidst Positive Drug Developments and Robust Financial Position

Analyst Gil Blum from Needham maintained a Buy rating on Celcuity and decreased the price target to $70.00...

2M ago

CELC

Celcuity Inc. Reports Promising Q2 2025 Results

Celcuity Inc. ( ($CELC) ) has released its Q2 earnings. Here is a breakdown of the information Celcuity...

2M ago

CELC

Celcuity reports Q2 EPS (93c), consensus (85c)

“We have had an eventful past few months at Celcuity (CELC). Last month, we announced positive topline data...

2M ago

CELC

CELC FAQ

What was Celcuity Inc.’s price range in the past 12 months?

Celcuity Inc. lowest stock price was $7.58 and its highest was $63.06 in the past 12 months.

What is Celcuity Inc.’s market cap?

Celcuity Inc.’s market cap is $1.92B.

When is Celcuity Inc.’s upcoming earnings report date?

Celcuity Inc.’s upcoming earnings report date is Nov 17, 2025 which is in 44 days.

How were Celcuity Inc.’s earnings last quarter?

Celcuity Inc. released its earnings results on Aug 14, 2025. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.884 by -$0.156.

Is Celcuity Inc. overvalued?

According to Wall Street analysts Celcuity Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Celcuity Inc. pay dividends?

Celcuity Inc. does not currently pay dividends.

What is Celcuity Inc.’s EPS estimate?

Celcuity Inc.’s EPS estimate is -1.02.

How many shares outstanding does Celcuity Inc. have?

Celcuity Inc. has 42,426,712 shares outstanding.

What happened to Celcuity Inc.’s price movement after its last earnings report?

Celcuity Inc. reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.884. Following the earnings report the stock price went down -0.193%.

Which hedge fund is a major shareholder of Celcuity Inc.?

Currently, no hedge funds are holding shares in CELC

Celcuity Stock Smart Score

Outperform

Fundamentals

Return on Equity

-134.54%

Trailing 12-Months

Asset Growth

-37.24%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Celcuity Inc.

Celcuity Inc. is a biotechnology company focused on discovering new cancer sub-types and developing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Operating primarily within the healthcare sector, Celcuity’s core product, CELsignia, is a platform that identifies the dynamic cellular activity in a patient's cancerous cells, helping to determine the most effective targeted therapy for their treatment.

Celcuity (CELC) Earnings & Revenues

Historic Earnings Reports

CELC Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a strong set of highlights with significant clinical trial progress, patent extension, and financial fortification, although it was balanced by increased losses and expenses.View all CELC earnings summaries

CELC Stock 12 Month Forecast

Average Price Target

$76.33

▲(51.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","111":"$111","33.75":"$33.8","59.5":"$59.5","85.25":"$85.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$76.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,33.75,59.5,85.25,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.22,50.20307692307692,55.18615384615384,60.169230769230765,65.15230769230769,70.13538461538461,75.11846153846153,80.10153846153847,85.08461538461538,90.06769230769231,95.05076923076922,100.03384615384616,105.01692307692308,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.22,47.613076923076925,50.00615384615384,52.39923076923077,54.79230769230769,57.18538461538461,59.57846153846154,61.97153846153846,64.36461538461538,66.75769230769231,69.15076923076923,71.54384615384615,73.93692307692308,{"y":76.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.22,46.74153846153846,48.26307692307692,49.784615384615385,51.30615384615385,52.82769230769231,54.34923076923077,55.87076923076923,57.392307692307696,58.91384615384615,60.43538461538462,61.956923076923076,63.47846153846154,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.49,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >